Recent News

• 06.09.2025 - Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
• 06.09.2025 - Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
• 06.02.2025 - Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
• 06.02.2025 - Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
• 05.19.2025 - Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
• 05.19.2025 - Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
• 05.13.2025 - Humacyte First Quarter 2025 Financial Results and Corporate Update
• 05.13.2025 - Humacyte First Quarter 2025 Financial Results and Corporate Update

Recent Filings

• 05.22.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - DEF 14A Other definitive proxy statements